Pharmaceutical News

RSS

$Analysis shows Teriparatide reduces fracture risk independent of bone turnover$

Analysis shows Teriparatide reduces fracture risk independent of bone turnover

Data presented yesterday at the 26th annual meeting of the American Society for Bone and Mineral Research (ASBMR) show that the ability of teriparatide to prevent fractures remained consistent regardless of pretreatment bone turnover status.

5 Oct 2004

Immediate voluntary world-wide withdrawal of Vioxx (rofecoxib)

Pharmaceutical company, Merck Sharp & Dohme has announced an immediate voluntary world-wide withdrawal of the drug, Vioxx (rofecoxib), commonly used for patients with rheumatoid or osteoarthritis.

4 Oct 2004

FDA fast tracks Genaera's drug for the treatment of wet age-related macular degeneration

Genaera Corporation has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to squalamine, an intravenously administered, first in class, small molecule anti-angiogenic drug for the treatment of "wet" age-related macular degeneration (AMD).

4 Oct 2004

First U.S. program to allow citizens to purchase lower cost, safe prescription drugs from Europe and Canada

Illinois Gov. Rod R. Blagojevich and Congressman Rahm Emanuel (D-Chicago) were joined in Chicago today by Wisconsin Governor Jim Doyle to launch the new I-SaveRx prescription drug importation program -- the first program in the nation to allow citizens to purchase lower cost, safe prescription drugs from Europe and Canada.

4 Oct 2004

Bristol-Myers Squibb submits New Drug Application to the U.S. Food and Drug Administration for entecavir

Bristol-Myers Squibb has announced the submission of a New Drug Application to the U.S. Food and Drug Administration for entecavir, an investigational antiviral agent under development for the treatment of chronic Hepatitis B.

4 Oct 2004

MHRA advice following withdrawal of Vioxx (rofecoxib)

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued advice following the withdrawal of a widely-used pain-killer and anti-inflammatory drug Vioxx (rofecoxib).

4 Oct 2004

Chiron grants a non-exclusive license to the German Red Cross

Chiron Corporation has announced that it has granted a non-exclusive license to the Blood Transfusion Centers of the German Red Cross (Blutspendediensten des Deutsche Rotes Kreuz, or DRK) for use of the company's HIV-1 and hepatitis C virus (HCV) technology for use in molecular probe "home brew" blood screening.

4 Oct 2004

Data demonstrate that Celebrex does not increase the risk of heart attack or stroke in patients with arthritis and pain

Pfizer has said that three large long-term Celebrex (celecoxib capsules) studies involving more than 6,000 patients have not shown any significant safety issues and are expected to continue to completion.

4 Oct 2004

Approval of Abilify (aripiprazole) for the treatment of acute bipolar mania

Bristol-Myers Squibb and Otsuka Pharmaceutical have announced that the U.S. Food and Drug Administration (FDA) has approved Abilify (aripiprazole) for the treatment of acute bipolar mania, including manic and mixed episodes associated with bipolar disorder.

4 Oct 2004

Australian nanotech Starpharma to develop a second generation microbicide for the prevention of infection by HIV

Melbourne-based nanotechnology company Starpharma will lead a consortium to develop a second generation microbicide for the prevention of infection by HIV and other sexually transmitted diseases (STDs).

30 Sep 2004

ID Biomedical awarded US$9.5 million to develop its cell culture-based influenza vaccine

ID Biomedical announced today that it has been awarded a US$9.5 million grant from the U.S. National Institutes of Health (NIH) to develop its cell culture-based influenza vaccine.

29 Sep 2004

Biomira and Merck announce fast track status for liposome vaccine

Biomira and Merck KGaA have announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track status to the investigation of BLP25 Liposome Vaccine (L-BLP25) for its proposed use in the treatment of non-small cell lung cancer (NSCLC).

29 Sep 2004

Schwarzenegger signs AIDS Pharmacy Bill

The AIDS Healthcare Foundation (AHF) has praised Governor Schwarzenegger for signing AB 1367 (Darrell Steinberg, D, Sacramento John Laird, D, Santa Cruz).

29 Sep 2004

Chiron CEO to appear before the U.S. Senate Special Committee on Aging

Chiron Corporation announced that president and chief executive officer Howard Pien will appear before the U.S. Senate Special Committee on Aging in Washington, D.C., today in a hearing titled, "Combating the Flu: Keeping Seniors Alive."

28 Sep 2004

New capsule, made from fish gelatin, should end fears of viral infections such as BSE and vCJD

An alternative to mammalian gelatin for use in pharmaceutical soft capsules has been discovered by researchers at the School of Pharmacy and Chemistry at Liverpool John Moores University.

28 Sep 2004

Half of sildenafil samples purchased on the internet were fake

Around half of the Viagra samples purchased on the Internet were counterfeit, according to researchers who are today announcing a new technique that detects counterfeit medicines at the British Pharmaceutical Conference.

27 Sep 2004

New drug application to market ramelteon for insomnia

Takeda Global Research & Development Center announced today that it has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) to market ramelteon (TAK-375), its investigational drug for insomnia.

26 Sep 2004

Ranbaxy receives FDA approval to market Loratadine and Pseudoephedrine Sulfate extended release tablets

Ranbaxy Pharmaceuticals, a wholly-owned subsidiary of Ranbaxy Laboratories Limited of New Delhi, India, announced today that RLL has received approval from the U. S. Food and Drug Administration to manufacture and market Loratadine and Pseudoephedrine Sulfate Extended Release Tablets

26 Sep 2004

Drug companies and FDA crack down on Canadian drug importation to protect profits

With an election on the horizon, and Canadian pharmacies proving to be as safe as U.S. counterparts, the Food and Drug Administration and big pharma are increasing efforts to prevent Canadian drug importation.

26 Sep 2004

Drug shortages are having major negative effects on patient care and hospital costs

A study to be published in the October 1, 2004, issue of the American Journal of Health-System Pharmacy finds that ongoing drug shortages are having far-ranging, negative effects on patient care and hospital costs.

26 Sep 2004

Pharmaceutical News

Analysis shows Teriparatide reduces fracture risk independent of bone turnover

Immediate voluntary world-wide withdrawal of Vioxx (rofecoxib)

FDA fast tracks Genaera's drug for the treatment of wet age-related macular degeneration

First U.S. program to allow citizens to purchase lower cost, safe prescription drugs from Europe and Canada

Bristol-Myers Squibb submits New Drug Application to the U.S. Food and Drug Administration for entecavir

MHRA advice following withdrawal of Vioxx (rofecoxib)

Chiron grants a non-exclusive license to the German Red Cross

Data demonstrate that Celebrex does not increase the risk of heart attack or stroke in patients with arthritis and pain

Approval of Abilify (aripiprazole) for the treatment of acute bipolar mania

Australian nanotech Starpharma to develop a second generation microbicide for the prevention of infection by HIV

ID Biomedical awarded US$9.5 million to develop its cell culture-based influenza vaccine

Biomira and Merck announce fast track status for liposome vaccine

Schwarzenegger signs AIDS Pharmacy Bill

Chiron CEO to appear before the U.S. Senate Special Committee on Aging

New capsule, made from fish gelatin, should end fears of viral infections such as BSE and vCJD

Half of sildenafil samples purchased on the internet were fake

New drug application to market ramelteon for insomnia

Ranbaxy receives FDA approval to market Loratadine and Pseudoephedrine Sulfate extended release tablets

Drug companies and FDA crack down on Canadian drug importation to protect profits

Drug shortages are having major negative effects on patient care and hospital costs

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News